Acelrx pharmaceuticals announces publication of study evaluating anticoagulation practices for continuous renal replacement therapy in the united states

Use of crrt increased during covid and remained at these higher utilization levels study results demonstrate challenges physicians have with heparin and citrate, the two currently available crrt anticoagulants  san mateo, calif. , dec. 12, 2023 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a quantitative market research study evaluating current u.s. physician anticoagulation use during continuous renal replacement therapy (crrt) in patients with acute kidney injury in the intensive care unit.
ACRX Ratings Summary
ACRX Quant Ranking